FMP
Caladrius Biosciences, Inc.
CLBS
NASDAQ
Inactive Equity
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
0.426 USD
-0.08579999 (-20.12%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. David Mazzo
sector
Healthcare
industry
Biotechnology
website
https://www.caladrius.comexchange
NASDAQ
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences...
CIK
0000320017
ISIN
US1280582032
CUSIP
128058203
Address
110 Allen Rd
Phone
19088420100
Country
US
Employee
27
IPO Date
Nov 3, 1995
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CLBS Financial Summary
CIK
0000320017
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
128058203
ISIN
US1280582032
Country
US
Price
0.43
Beta
0.91
Volume Avg.
0
Market Cap
3.35M
Shares
-
52-Week
-
DCF
2.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.08
P/B
-
Website
https://www.caladrius.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CLBS News
It looks like there's no news available.
